166 related articles for article (PubMed ID: 1683561)
1. Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts.
Singh P; Townsend CM; Poston GJ; Reubi JC
J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):759-67. PubMed ID: 1683561
[TBL] [Abstract][Full Text] [Related]
2. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice.
Poston GJ; Townsend CM; Rajaraman S; Thompson JC; Singh P
Pancreas; 1990 Mar; 5(2):151-7. PubMed ID: 2156257
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells.
Smith JP; Rickabaugh CA; McLaughlin PJ; Zagon IS
Am J Physiol; 1993 Jul; 265(1 Pt 1):G149-55. PubMed ID: 8338163
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.
Povoski SP; Zhou W; Longnecker DS; Bell RH
Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527
[TBL] [Abstract][Full Text] [Related]
5. Human pancreatic cancer cell lines do not express receptors for somatostatin.
Gillespie J; Poston GJ; Schachter M; Guillou PJ
Br J Cancer; 1992 Sep; 66(3):483-7. PubMed ID: 1355659
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
Celinski SA; Fisher WE; Amaya F; Wu YQ; Yao Q; Youker KA; Li M
J Surg Res; 2003 Nov; 115(1):41-7. PubMed ID: 14572771
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of a long-acting somatostatin analogue on EGF-stimulated cell proliferation in Capan-2 cells.
Burghardt B; Barabás K; Marcsek Z; Flautner L; Gress TM; Varga G
J Physiol Paris; 2000; 94(1):57-62. PubMed ID: 10761690
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas.
Bell RH; Kuhlmann ET; Jensen RT; Longnecker DS
Cancer Res; 1992 Jun; 52(12):3295-9. PubMed ID: 1596887
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines.
Smith JP; Liu G; Soundararajan V; McLaughlin PJ; Zagon IS
Am J Physiol; 1994 Jan; 266(1 Pt 2):R277-83. PubMed ID: 8304551
[TBL] [Abstract][Full Text] [Related]
10. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization.
Zhou W; Povoski SP; Longnecker DS; Bell RH
Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479
[TBL] [Abstract][Full Text] [Related]
11. The somatostatin receptor on isolated pancreatic acinar cell plasma membranes. Identification of subunit structure and direct regulation by cholecystokinin.
Sakamoto C; Goldfine ID; Williams JA
J Biol Chem; 1984 Aug; 259(15):9623-7. PubMed ID: 6146617
[TBL] [Abstract][Full Text] [Related]
12. Distribution of somatostatin receptors in RINm5F insulinoma cells.
Sullivan SJ; Schonbrunn A
Endocrinology; 1988 Mar; 122(3):1137-45. PubMed ID: 2893729
[TBL] [Abstract][Full Text] [Related]
13. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
[TBL] [Abstract][Full Text] [Related]
14. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
[TBL] [Abstract][Full Text] [Related]
15. Effects of cholecystokinin octapeptide on a pancreatic acinar carcinoma in the rat.
Hajri A; Damgé C
Pharm Res; 1998 Nov; 15(11):1767-74. PubMed ID: 9834001
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.
Upp JR; Olson D; Poston GJ; Alexander RW; Townsend CM; Thompson JC
Am J Surg; 1988 Jan; 155(1):29-35. PubMed ID: 2893555
[TBL] [Abstract][Full Text] [Related]
17. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.
Corp ES; McQuade J; Moran TH; Smith GP
Brain Res; 1993 Sep; 623(1):161-6. PubMed ID: 8221086
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
Zhou W; Povoski SP; Bell RH
J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
[TBL] [Abstract][Full Text] [Related]
19. CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.
Stark HA; Sharp CM; Sutliff VE; Martinez J; Jensen RT; Gardner JD
Biochim Biophys Acta; 1989 Feb; 1010(2):145-50. PubMed ID: 2463851
[TBL] [Abstract][Full Text] [Related]
20. A reduced pancreatic protein secretion in response to cholecystokinin (CCK) in the obese Zucker rat correlates with a reduced receptor capacity for CCK.
Praissman M; Izzo RS
Endocrinology; 1986 Aug; 119(2):546-53. PubMed ID: 3015550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
